Fecal Microbiota Transplantation: Information for the Pediatrician
Maria Oliva‐Hemker, Stacy A. Kahn, William J. Steinbach, SECTION ON GASTROENTEROLOY, HEPATOLOGY, AND NUTRITION, Mitchell B. Cohen, David Brumbaugh, Conrad R. Cole, Jennifer L. Dotson, Sanjiv Harpavat, Jenifer R. Lightdale, Daniel Mallon, Maria Oliva‐Hemker, Debra L. Burrowes, Yvonne Maldonado, Sean T. O’Leary, Monica I. Ardura, Ritu Banerjee, Kristina A. Bryant, James D. Campbell, Mary T. Caserta, Chandy C. John, Jeffrey S. Gerber, Athena P. Kourtis, Adam J. Ratner, José R. Romero, Samir S. Shah, Kenneth M. Zangwill, William J. Steinbach, David W. Kimberlin, Elizabeth D. Barnett, Ruth Lynfield, Mark H. Sawyer, Henry H. Bernstein, Amanda Cohn, Karen M. Farizo, Lisa M. Kafer, David Kim, Eduardo López‐Medina, Denee Moore, Lakshmi Panagiotakopoulos, Laura Sauvé, Neil S. Silverman, Jeffrey R. Starke, Kay M. Tomashek, Jennifer M. Frantz
Abstract
Fecal microbiota transplantation (FMT) involves the delivery of an entire microbial community from a healthy donor to a recipient with the intention of ameliorating or curing a specific disease. Current evidence strongly supports a role for FMT in the treatment of Clostridiodes difficile infection, with cure rates of approximately 80% to 90%. This success has led to increasing attention for FMT as a potential therapeutic intervention for other conditions associated with disturbances of the intestinal microbiome, including inflammatory bowel diseases, autism spectrum disorder, and obesity. This clinical report endorses the joint society statement by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition and is meant to provide the general pediatrician with a broad overview to enable appropriate guidance to families seeking FMT as treatment of a child's condition.